



Date: 12/08/2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Script Code : 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : BAJAJHCARE
--	---

Dear Sir/Madam,

Sub : Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter ended June 30, 2022.

The Board of Directors at its Meeting held today has inter alia, considered and approved the following:

- the unaudited Financial Statements for the quarter ended June 30, 2022, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose the following:

(i) Unaudited Financial Results for the quarter ended June 30,, 2022 along with limited review report;

- Revision in remuneration of Mr. Sajankumar Bajaj, Chairman & Managing Director of the Company, subject to approval of shareholders at the ensuing Annual General Meeting.
- Revision in remuneration of Mr. Anil Jain, Managing Director of the Company, subject to approval of shareholders at the ensuing Annual General Meeting.
- Notice of 29th Annual General Meeting.

The above information is also available on the Company's website at www.bajajhealth.com. This is for your information and records.

We wish to inform you that Board Meeting commenced today at 04.00 p.m. and concluded at 5.45 p.m.

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors
of Bajaj Healthcare Limited


Mr. Aakash Keshari
Company Secretary



BAJAJ HEALTHCARE LIMITED

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

Chaturvedi & Agrawal


Chartered Accountants


Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi & Agrawal
Chartered Accountants
FRN: 101717W


Rasik Chaturvedi
M. no: 039524
UDIN: 220395240X1U4825



Date: 12th August 2022
Place: Mumbai



BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30 th June, 2022
(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Year Ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from operations	17,206.88	17,571.36	18,568.87	67,988.98
II. Other Income	66.99	44.81	67.95	144.41
III. Total Revenue (I+II)	17,273.88	17,616.17	18,636.82	68,133.39
IV. Expenses				
(a) Cost of materials consumed (Including Other Direct Expenses)	15,215.24	14,163.23	15,444.24	49,982.29
(b) Changes in Inventories of Finished Good	(2,204.39)	(806.20)	(1,992.56)	(377.00)
(c) Employee benefits expense	992.05	1,086.46	964.34	4,110.87
(d) Finance Costs	382.48	448.62	279.33	1,262.38
(e) Depreciation and amortisation expense	653.29	423.97	413.07	1,763.66
(e) Other expenses	619.63	607.19	803.05	2,422.72
Total Expenses	15,658.30	15,923.27	15,911.47	59,164.93
V. Profit Before Tax	1,615.57	1,692.89	2,725.35	8,968.46
VI. Tax Expense				
(a) Current tax	426.00	385.00	814.00	2,250.00
(b) Earlier Years	-	(360.77)	(0.09)	(358.73)
(c) Deferred Tax	-12.30	(78.54)	(10.26)	(61.40)
Total Tax Expenses	413.70	-54.31	803.64	1,829.87
VII. Profit (Loss) for the Period	1,201.88	1,747.20	1,921.71	7,138.59
VIII. Other comprehensive Income				
(i) Items that will not be reclassified to profit or loss	-	9.23	-	9.23
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(2.32)	-	(2.32)
(iii) Items that will be reclassified to profit or loss	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Comprehensive Income for the Period	1,201.88	1,754.11	1,921.71	7,145.49
IX. Paid-up Equity Share Capital (Face Value Rs. 5/-)	1,379.92	1,379.92	1,379.92	1,379.92
X. Other Equity excluding Revaluation Reserve	-	-	-	31,468.63
XI. Earnings Per Share (Face Value Rs. 5/-) (Not Annualised for Quarter and Year Ended)				
(a) Basic (in Rs.)	4.35	6.33	6.96	25.87
(b) Diluted (in Rs.)	4.35	6.33	6.96	25.87

Note :

- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on August 12, 2022.
- b) The above audited financial results for the Quarter Ended June 30, 2022 have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 (Act) read with relevant rules-Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
- c) Segment reporting is not applicable, the Company as a whole operates under single Chief Operating Decision Maker (CODM) w.e.f April 1st, 2022, pursuant to Consolidation of the activities of API and Formulation business under Pharma as one segment.
- d) Pursuant to the approval of the shareholders by way of Postal Ballot on September 17, 2021, each Equity Share of Rs. 10/- each fully paid up was sub- divided into 2 Equity Shares of Rs. 5/- each fully paid up, with effect from the record date September 29, 2021. Consequently, the basic and diluted earnings per share have been adjusted retrospectively for all the periods presented in the Standalone Financial Results of the Company on the basis of the new number of equity shares in accordance with the provisions of applicable Indian AS.
- e) The Figures for quarter ended March 31, 2022 are balancing figure between audited figures of full financial year and published unaudited figures upto the third quarter of the financial year then ended.



By Order of the Board
For Bajaj Healthcare Limited

Sajankumar Bajaj
Chairman & Managing Director
DIN : 00225950

Date: August 12, 2022
Place: Thane